Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Match Group Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Match Group Inc trades at $42.32 (market cap $9.72B). The key difference: Match Group Inc is far larger — about 3.4× Dyne Therapeutics Inc. Common Stock's market cap, and Match Group Inc pays a 1.89% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Match Group Inc for 115 Days on average.
| DYN | MTCH | |
|---|---|---|
Market Cap | $2.86B | $9.72B |
Volume | 3,341,579 | 4,140,020 |
Sector | Health | Media |
52-Week High | $26.78 | $44.40 |
52-Week Low | $14.60 | $28.90 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $2.18B | $12.69B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
MTCH trades at $42.40, up 2.12% today, with a bullish technical signal and strong support at $41. The company reported a net income margin of 20.17% for 2025, with Q2 2026 EPS beating expectations. Operating cash flow reached $1.08B in 2025, and a $0.20 dividend is scheduled for October 2026. Recent news highlights product innovation at Tinder and growth at Hinge.
The outlook is positive with a consensus price target of $42.29, though high debt levels and competitive pressures pose risks. Analyst sentiment is bullish with 53% buy ratings. Revenue stability and margin expansion support upside potential, but investors should monitor execution on Tinder's turnaround and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
